PROJΞcTS

Repositioning TEE786

recessive dystrophic epidermolysis bullosa

Epidermolysis bullosa is a disease affecting the function of type 7 collagen at the interface between the dermis and the epidermis.

APTEEUS wishes to engage its first drug candidate in the development of a topical skin product to treat this pathology. TEE786 is a molecule whose demonstrated pharmacological activities will have a beneficial effect on wound healing in patients with bullous epidermolysis.  Success in this first development may open up several extensions of indications in other dermatoses.

Evaluation of the drug candidate TEE786...
0%

Individualized discovery

Fumarase deficiency

67624163_102775167744702_964300516790108160_n

Fumarase is an enzyme mainly involved in the krebs cycle, essential for the production of energy by the mitochondria. Its deficiency leads to fumaric aciduria (ORPHA:24), a disease that disrupts the normal development of the child. It is an ultra-rare disease with about 100 cases reported to date.

Apteeus established a collaboration with a canadian company Modelis to develop a model of the disease. 

In vitro model development
0%

repositioning TEE703 - 1482

Acid ceramidase deficiency

asap

Ceramidase (acid) is a lysosomal enzyme involved in the recycling and catabolism of ceramides. Its deficiency results in the accumulation of ceramides in the lysosome and other organelles and disrupts the metabolism of cells (ORPHA: 333 and 2590). Proximal spinal muscular atrophy-progressive myoclonic epilepsy or SMA-PME syndrome is a manifestation of ceramidase deficiency affecting only about ten patients. This is an ultra-rare disease. Farber’s disease, whose symptoms are more severe and early, affect a few more patients.

After several months of individualized research, Apteeus identified several drug candidates. A child with this disease is currently receiving some of them. Apteeus remains involved in the biological monitoring of the child in order to obtain evidence proving the effectiveness of the treatment in limiting the worsening of symptoms. Other children with the same disease are also in the study.

Drug Candidate Identification
0%

Individualized discovery

Hunter Syndrome, MPS2

logo

Mucopolysaccharidosis type II (MPSII) (or Hunter syndrome) is a disease which affects the function of a lysosomal enzyme called iduronate-2-sulfatase. This enzyme is able to digest glycosaminoglycans (long linear polysaccharides) and its deficiency leads to an accumulation of these polysaccharides in whole the body. This accumulation impairs the biological balance.

Apteeus commits to this project in order to test 2600 compounds from its library on cells from a patient affected by MPSII. Based on LC-MS technology, Apteeus investigates to restore the level of glycosaminoglycans. A drug could eventually be useful as an add-on of enzyme replacement therapy.

in vitro model development
0%

repositioning TEE886

ACOX1 deficiency

Rond_MHM

The ACOX1 protein, for Acyl-CoEnzymeA oxidase type 1, is a peroxisomal protein involved in the beta-oxidation of very long chain fatty acids in the peroxisome (ORPHA:2971). Peroxisomal acyl-CoA oxidase deficiency is an ultra-rare disorder. Its prevalence is unknown. Only a few dozen cases have been described in the medical literature.

It is our technology based on liquid chromatography coupled with mass spectrometry that has enabled us to identify TEE886, a drug candidate that restores a normal level of very long fatty acids in the cells of an ACOX1 deficient child. The child is currently monitored to evaluate the progress of his pathology under treatment.

Clinical evaluation of TEE886
0%

Individualized discovery

krabbe disease

38498830_2081867755409106_7880223265317191680_n

Krabbe disease (or globoid cell leukodystrophy) is a lysosomal disorder affecting the white matter of the central (CNS) and peripheral nervous systems (PNS) (ORPHA:487). It is a deficiency of the enzyme galactocerebrosidase (GALC) that causes the accumulation of psychosine toxic to oligodendrocytes and consequently demyelination of the CNS and PNS.

We are currently working on the development of an in vitro model that would allow us to identify drugs capable of limiting the impact of this disease.

in vitro model development
0%

repositioning TEE1121

d-bifonctionnal protein deficiency

43788044_444876402585140_2995922869315174400_n

Bi-functional protein D is a peroxisomal enzyme involved in the beta-oxidation of very long fatty acids. Its deficiency leads to an accumulation of very long fatty acids and disrupts the other functions of the cell (ORPHA:300). D-bifunctional protein deficiency is estimated to affect 1 in 100,000 newborns. The prevalence is very low, it is an ultra-rare disorder.

Apteeus used liquid chromatography coupled with mass spectrometry to highlight the accumulation of very long chain fatty acids in Noé’s cells in culture. Miniaturized and automated, the test has made it possible to identify several drugs. Unfortunately time and disease have been against us. We were unable to assess the benefit-risk balance of its use on Noé. This program will benefit to other patients suffering from the same disorder.

Clinical evaluation of TEE1121
0%

INDIVIDUALIZED DISCOVERY

PEX deficiency

43788044_444876402585140_2995922869315174400_n

The peroxisome is a cellular organelle involved in the metabolism of fatty acids and amino acids, the reduction of reactive oxygen derivatives and the synthesis of plasmalogens. The proteins necessary for peroxisomes are synthesized outside of the latter, in the cytosol. These are in particular the peroxins, responsible for the protein import system and encoded by the PEX genes. Deficiency in any of the peroxins causes peroxisomopathy.

We have developed a screening test allowing, by LCMS-MS, to assay the specific lipid derivatives of peroxisomes. Several children will participate in this research program aimed at identifying drugs capable of limiting the impact of a peroxin deficiency.

in vitro model development
0%